Skip to main content

Table 3 Basic description of the participating women

From: Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study

  Total N = 1456
  Surgery No surgery
  1432 (98.35%) 24 (1.65%)
Age, yearsa 57.604 (11.917) 80.575 (11.257)
Charlson comorbidity indexa 0.325 (0.752) 0.958 (1.197)
Initial treatment   
Conservative 648 (45.25%)
Simple mastectomy 203 (14.18%)
Radical mastectomy 38 (2.65%)
Radical modified mastectomy 46 (3.21%)
Neoadjuvant therapy 165 (11.52%) 22 (91.67%)
Adjuvant therapy   
Chemotherapy1 455 (31.77%)  
ACT 166 (11.59%)  
TAC 80 (5.59%)  
CMF 8 (0.56%)  
FEC 42 (2.93%)  
FEC-Taxane 41 (2.86%)  
TC 35 (2.44%)  
Other 88 (6.15%)  
Radiotherapy (yes) 1126 (78.63%)  
Hormone therapy 1146 (80.03%)  
Tamoxifen 484 (33.8%)  
Tamoxifen +GnRH analogues2 50 (3.49%)  
Tamoxifen +Aromatase inhibitors 12 (0.84%)  
Aromatase inhibitors 639 (44.62%)  
Others 26 (1.82%)  
TNM3   
0 135 (9.43%) 0
I 683 (47.7%) 2 (8.33%)
II 453 (31.63%) 5 (20.83%)
III 134 (9.36%) 4 (16.67%)
IV 18 (1.26%) 11 (45.83%)
  1. 1.-Chemotherapy:
  2. ACT Adriamycin/ doxorrubicine, cyclophosphamide + taxane (docetaxel / paclitaxel),
  3. TAC docetaxel, Adriamycin, cyclophosphamide,
  4. CMF cyclophosphamide, Methotrexate 5-Fluorouracil
  5. FAC 5-fluorouracil, Adriamycin (Doxorubicin), cyclophosphamide- FEC: 5-fluorouracil, epirubicin, cyclophosphamide
  6. FEC-Taxane FEC + paclitaxel
  7. TC Taxane, cyclophosphamide
  8. 2.- GnRH Gonadotropin-releasing hormone analogues
  9. 3.-pTNM pathological tumor-node-metastasis staging in patients who underwent surgery
  10. aMeans and, in brackets, standard deviation